Quote from: ajasfolks2 on February 08, 2017, 07:46:32 AM
Putting this here -- need to research -- feel free to comment
Allergic Tension Fatigue Syndrome
and depression as poss side effect of some food allergy treatments (OIT esp??) . . . .
Not necessarily about anxiety or depression due to fear of ingesting allergen(s), but instead an actual physical or chemical reaction that is the body's response to the allergen? Does that makes sense?
Quote from: Suzie Fromer on December 12, 2016, 12:42:40 PM
Covered by insurance, fyi.
QuoteDr. Dave Stukus @AllergyKidsDoc
.@suziefro please do me a favor - take my name off your site. You know you stole this quote & are misrepresenting me. pic.twitter.com/Z1x09925Bw[\quote]
twitter.com/AllergyKidsDoc/status/806347634562793472/photo/1
This post does not constitute an endorsement of Allergy Bro. On this single issue I will not let any of my activity be complicit in any intended or unintended attempt to co-opt his.
Quote from: name on September 28, 2016, 11:02:00 PM
So, for the folks who have been doing OIT w/o FDA approval, enlighten me on how it works with the insurance plans. I ain't judging you on the choice to pursue OIT, I just wanna know if insurance is covering it. Something I heard a while ago is coming back to me now about FARE trying to establish a clinical network. If you've been doing OIT for a while do you know if your office is part of the FARE clinical network or do they essentially don't care a fig about FARE's clinical club?
Quote from: name on September 28, 2016, 10:47:12 PM
AYFKM. Not enough of a lesson learned with Mylan? Icarus much? I'm so incredibly glad there's NO RELATIONSHIP between the advisory board and Aimmune. I'm sure 'Dan' rode the Tardis in from another dimension with no Aimmune overlap whatsoever. For the record, I have zippo to do with that wack OIT101 group riding my posts.
Good to know you're pleased, James.QuoteUntil resigning to become Chief Medical Officer of Aimmune, Dr. Adelman was a member of the prestigious Research Advisory Board of Food Allergy Research & Education (FARE), the world's largest private funder of food allergy research. For several years, he was actively involved in reviewing FARE's research funding and helped to shape the organization's overall research strategy.
"We're deeply grateful for the contributions Dan has made as a member of our Research Advisory Board, and we're pleased to see him join Aimmune," said James R. Baker, Jr., M.D., FARE CEO and Chief Medical Officer. "Dan's leadership and clinical expertise will be great assets as Aimmune continues to progress toward what would be the first FDA-approved oral immunotherapy for food allergies. This treatment could make a great impact on the lives of millions of people at risk from peanut allergy."
For timeline purposes this was released right before Epigate really blew up. Dated Jun 21, 2016.
businesswire.com/news/home/20160621005527/en/Aimmune-Therapeutics-Appoints-Daniel-Adelman-M.D.-Chief
Quote from: lakeswimr on April 02, 2016, 06:02:49 PMThis is key, I think, when considering the place Aimmune seems to occupy in moving this type treatment forward. I'd been considering OIT for a few years but without any allergists in my state/city offering the treatment I hesitated. I kept picturing myself on the highway in the middle of nowhere with my daughter reacting and I'd shelve the idea for another month or so.
Did you see the recent issue of Allergic Living? It was like half the magazine was an advertisement for Aim mune. There was the opening by the editor praising it, the article on Aim mune itself that, and then an article from FARE pushing for it. I didn't see a mention of the link between FARE an Aim mune. I'm not actually down on Aim mune but something about all that didn't feel quite right to me.
I think Aim mune could help more people get OIT and I think that done properly, OIT will work on most, but not all, people with FAs. I think it will make more doctors feel comfortable doing it. Not all will want to do it or be ready for all that it involves, even if they use a pre-packaged pill. I do not think using this pill is better than the way it is currently done in OIT clinics, though.
Quote from: CMdeux on May 31, 2015, 12:18:58 PM
I also don't like that a food protein is being moved into monetizing position here with a PATENT-- no, no, no.
One reason why SCIT has been relatively affordable and available to hundreds of thousands of patients over the past six decades is that the extracts are NOT "patent" materials.
This is like patenting BRC genes-- I don't like that either-- because when you start making naturally-occurring nucleic acids, proteins, and the like someone's intellectual property, you are CONTROLLING HOW THEY CAN BE USED. Even for research purposes.
My gosh I don't think that is a good thing here. NO way.
QuoteA decade ago, US law said human genes were patentable — which meant patent holders had the right to stop anyone from sequencing, testing or even looking at a patented gene. Troubled by the way this law both harmed patients and created a barrier to biomedical innovation, Tania Simoncelli and her colleagues at the ACLU challenged it. In this riveting talk, hear the story of how they took a case everybody told them they would lose all the way to the Supreme Court.